| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.7 | 0.0003 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0009 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0009 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0009 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |